Deepcell

Executive Summary

Deepcell is a biotechnology company pioneering an integrated platform that combines high-resolution live-cell imaging, AI-powered analysis, and gentle cell sorting to enable label-free, morphology-based single-cell analysis and enrichment. Founded in 2017 and headquartered in Menlo Park, California, Deepcell's REM-i platform addresses critical needs in oncology, drug discovery, and cell and gene therapy by transforming raw cell morphology into actionable biological insights. The company's technology allows researchers to analyze and sort viable cells without fluorescent labels, preserving cell health and enabling longitudinal studies. Deepcell operates in the diagnostics space and is privately held, with no disclosed funding or valuation. Its approach has the potential to accelerate research and development in precision medicine and cellular therapies.

Upcoming Catalysts (preview)

• H2 2026FDA Clearance for Clinical Diagnostic Use30% success
• Q3 2026Strategic Partnership with Major Pharmaceutical Company40% success
• Q4 2026Series B or C Funding Round Announcement50% success